Clinical trials: Hemophagocytic Lymphohistiocytosis
Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Rituximab Monotherapy for EBV-HLH and CAEBV
This study is a prospective single-arm clinical study, focusing on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection with only and mainly B lymphocytes of EBV…
- Trial name
- NCT05384743
- Testing
- Rituximab Monotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients
This prospective case-control study aims to evaluate the immune function and find PD-1 antibody efficacy predictors on Chronic Active Epstein-Barr Virus Infection and Epstein-Barr virus-associated hemophagocytic…
- Trial name
- NCT05841342
- Testing
- No intervention
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Chidamide, Hemophagocytic Lymphohistiocytosis
Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
Chidamide combines with VP-16 and methylprednisolone in HLH
- Trial name
- NCT05137522
- Testing
- Chidamide combines with VP-16 and methylprednisolone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Lymphohistiocytoses
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of several clinical conditions (e.g.
- Trial name
- NCT03985423
- Testing
- Emapalumab-Lzsg
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Swedish Orphan Biovitrum
EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis
Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
This study investigates the impact of letermovir prophylaxis on viral infections (including CMV, EBV, BKV, HHV-6/7, RSV, ADV, HSV, etc.) following allogeneic hematopoietic stem cell transplantation in pediatric patients with…
- Conditions
- EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir
- Trial name
- NCT07488728
- Testing
- Letermovir
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Children's Hospital
Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore…
- Conditions
- Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus, Bowel Resection
- Trial name
- NCT06131489
- Testing
- Segmental bowel resection combined with the DEP regimen
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Chediak-Higashi Syndrome, Graft Versus Host Disease
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
OBJECTIVES: I. Determine the efficacy of unrelated donor hematopoietic stem cell transplantation in the treatment of patients with life threatening hemophagocytic disorders. II.
- Conditions
- Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis
- Trial name
- NCT00006056
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fairview University Medical Center
Hemophagocytic Syndrome
Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study
Our three-step screening system uses commonly used clinical and laboratory parameters to effectively identify patients who may be at high risk of HLH, conduct etiology screening early for patients who meet the diagnostic criteria…
- Trial name
- NCT06614998
- Testing
- Patients diagnosed with HLH-94 should be treated as soon as possible
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Hemophagocytic Lymphohistiocytoses
HLH Patients - a Retrospective Study
Monocentric, observational, retrospective, no profit study aimed to analyze factors that are significantly impacting the outcome of patients diagnosed with HLH.
- Trial name
- NCT05531721
- Testing
- Observation
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- PRO-RIC (NCT04528355)
- Testing
- data collection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Paul Szabolcs
Hemophagocytic Lymphohistiocytosis
Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
Without therapy HLH is often fatal, and often rapidly fatal. The treatment protocol HLH-94 has improved survival markedly as compared to the survival earlier. We now aim to improve survival further.
- Trial name
- NCT00426101
- Testing
- Dexamethasone, Etoposide, Cyclosporin
- Where
- Sweden
- Volunteers
- 368 people
- Sponsor
- Karolinska University Hospital
CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, EBV
A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT
To evaluate the efficacy and safety of iNK cells infusion in patients with chronic active Epstein-Barr virus infection (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) after allogeneic hematopoietic stem…
- Conditions
- CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, EBV, Hemophagocytic Lymphohistiocytoses
- Trial name
- NCT06491719
- Testing
- NCR300（Allogenic Ipsc-derived Natural Killer cells ）
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Syndrome, T/NK-Cell Lymphoma
A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
To observe the efficacy and safety of Ruxolitinib and Etoposide combined with DDGP regimen ( cis-Platinum, Dexamethasone, Gemcitabine and Pegaspargase) in the first-line induction therapy of T cell lymphoma and NK/T cell…
- Trial name
- RUE-DDGP (NCT04999878)
- Testing
- Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhengzhou University
Extranodal NK/T-cell Lymphoma, Nasal Type
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).
- Trial name
- NCT04405375
- Testing
- gemcitabin, Pegaspargase, Etoposide
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Beijing Tongren Hospital
Hemophagocytic Lymphohistiocytosis
Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
This observational study is designed to determine the levels of pro-inflammatory markers in patients diagnosed with M-HLH, and to assess whether the cytokine profiles bear an IFNγ signature.
- Trial name
- NCT03259230
- Testing
- Blood Draws, Data Collection
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Swedish Orphan Biovitrum
Primary Hemophagocytic Lymphohistiocytosis
A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients
The goal of this post-authorization study is to describe safety and efficacy of emapalumab in treatment experienced Chinese patients with pHLH.
- Trial name
- NCT05744063
- Testing
- Emapalumab-Lzsg 5 MG/ML [Gamifant]
- Where
- 7 sites in China
- Volunteers
- 13 people
- Sponsor
- Swedish Orphan Biovitrum
Hemophagocytic Lymphohistiocytosis
Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology
To evaluate the clinical value of splenectomy as a treatment for relapsed haemophagocytic lymphohistiocytosis (HLH) in patient with unknown etiology.
- Trial name
- NCT02862054
- Testing
- splenectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Lymphohistiocytosis
DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH
This study aimed to investigate the efficacy and safety of DEP (liposomal doxorubicin, etoposide and methylprednisolone) together with PD-1 antibody as an treatment for EBV associated hemophagocytic lymphohistiocytosis.
- Trial name
- NCT05164978
- Testing
- DEP combine with PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS)
Investigation of Ferritin in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis
Retrospective analysis of ferritin, outcome and HLH-criteria in critically ill patients.
- Conditions
- Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Hemophagocytic Syndromes
- Trial name
- FERRITS (NCT02854943)
- Volunteers
- 2,623 people
- Sponsor
- Gunnar Lachmann
Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
A study designed to evaluate the efficacy, safety, immunogenicity, PK, and PD characteristics of Plonmarlimab in patients with relapsed/refractory rheumatic and immunologic disease-associated MAS, and to explore biomarkers…
- Trial name
- NCT07208058
- Testing
- Plonmarlimab
- Where
- 18 sites in China
- Volunteers
- 30 people
- Sponsor
- TJ Biopharma Co., Ltd.